Focused On-demand Library for Protein phosphatase 1 regulatory subunit 12A

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Myosin phosphatase-targeting subunit 1; Protein phosphatase myosin-binding subunit

Alternative UPACC:

O14974; B4DZ09; F8VWB4; Q2NKL4; Q569H0; Q86WU3; Q8NFR6; Q9BYH0


Protein phosphatase 1 regulatory subunit 12A, also known as Myosin phosphatase-targeting subunit 1, plays a pivotal role in cellular processes by regulating protein phosphatase 1C (PPP1C). It facilitates the binding to myosin and is involved in the dephosphorylation of PLK1, crucial for cell cycle progression. Additionally, it has the capability to counteract HIF1AN-mediated suppression of HIF1A activity, highlighting its significance in hypoxia signaling pathways.

Therapeutic significance:

The association of Protein phosphatase 1 regulatory subunit 12A with Genitourinary and/or brain malformation syndrome underscores its clinical relevance. Given its critical functions in cellular regulation and disease association, targeting this protein could offer novel therapeutic avenues for treating conditions characterized by urogenital malformations and brain abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.